Valuation Upgrade Spurs Rating Change
The most significant catalyst behind the rating upgrade is the shift in Makers Laboratories’ valuation grade from fair to attractive. The company currently trades at a price-to-earnings (PE) ratio of 37.11, which, while elevated, is comparatively reasonable within its peer group. Its price-to-book value stands at a modest 1.20, indicating the stock is trading close to its net asset value, a factor that appeals to value-conscious investors.
Further valuation metrics reinforce this positive outlook. The enterprise value to EBITDA ratio is 5.51, and the enterprise value to EBIT ratio is 7.95, both suggesting the stock is undervalued relative to earnings before interest, taxes, depreciation, and amortisation. Additionally, the EV to sales ratio of 0.58 highlights the company’s low market valuation relative to its revenue base. These figures contrast favourably with several peers in the Pharmaceuticals & Biotechnology sector, many of which are classified as very expensive or risky based on similar metrics.
Return on capital employed (ROCE) at 15.26% further supports the valuation upgrade, signalling efficient use of capital to generate profits. However, the return on equity (ROE) remains modest at 3.22%, reflecting limited profitability on shareholders’ funds, which tempers enthusiasm somewhat.
Our current monthly pick, this Mid Cap from Automobile Two & Three Wheelers, survived rigorous evaluation against dozens of contenders. See why experts are backing this one!
- - Rigorous evaluation cleared
- - Expert-backed selection
- - Mid Cap conviction pick
Financial Trend Shows Mixed Signals but Positive Quarterly Performance
Makers Laboratories has demonstrated encouraging financial performance in the latest quarter (Q4 FY25-26), with net sales reaching a quarterly high of ₹35.75 crores and PBDIT (profit before depreciation, interest, and taxes) peaking at ₹5.27 crores. The company’s debtors turnover ratio for the half-year stands at an impressive 7.08 times, indicating efficient collection of receivables and healthy operational cash flow.
Despite these positive quarterly results, the company’s long-term fundamentals remain somewhat weak. Operating profits have declined at a compound annual growth rate (CAGR) of -7.99% over the past five years, signalling challenges in sustaining profitability. Furthermore, the average ROE over this period is a low 4.67%, reflecting limited returns generated on equity capital.
Profitability has also been under pressure recently, with profits falling by 71.7% over the past year, even as the stock price has remained relatively flat, generating a 0.44% return over the same period. This divergence suggests that while the market has not fully priced in the earnings weakness, investors remain cautious.
Technicals and Market Performance
From a technical perspective, Makers Laboratories’ share price has experienced volatility. The stock closed at ₹147.80 on 23 June 2026, down 2.09% from the previous close of ₹150.95. The 52-week trading range spans from ₹109.00 to ₹186.70, indicating significant price movement over the past year.
Short-term returns have been negative, with a 10.02% decline over the past month and a slight 0.24% drop in the last week. However, the stock has outperformed the Sensex year-to-date, delivering a 25.10% return compared to the benchmark’s -9.54%. Over three years, Makers Laboratories has generated a 33.21% return, surpassing the Sensex’s 21.91% gain, though it lags over five and ten-year horizons.
These mixed technical signals, combined with the company’s micro-cap status and promoter majority ownership, suggest a cautious stance. The upgrade to Hold reflects this balanced view, recognising valuation appeal and recent financial improvements while acknowledging ongoing challenges.
Why settle for Makers Laboratories Ltd? SwitchER evaluates this Pharmaceuticals & Biotechnology micro-cap against peers, other sectors, and market caps to find you superior investment opportunities!
- - Comprehensive evaluation done
- - Superior opportunities identified
- - Smart switching enabled
Quality Assessment and Market Position
The company’s quality grade remains moderate, reflected in its Mojo Score of 50.0 and a Mojo Grade of Hold, upgraded from Sell. This score encapsulates various factors including financial health, earnings consistency, and operational efficiency. While Makers Laboratories has demonstrated some operational improvements, its weak long-term profit growth and low ROE constrain its quality rating.
Within the Pharmaceuticals & Biotechnology sector, the company is classified as a micro-cap, which inherently carries higher volatility and risk compared to larger peers. Its valuation attractiveness relative to peers such as Bliss GVS Pharma and Kwality Pharma, both rated very expensive, provides a relative advantage for investors seeking value in this segment.
Outlook and Investor Considerations
Investors should weigh the recent upgrade as a signal of stabilisation rather than a strong buy recommendation. The Hold rating reflects a cautious optimism based on improved valuation metrics and positive quarterly financials, balanced against weak long-term fundamentals and modest profitability.
Given the company’s micro-cap status and sector dynamics, investors with a higher risk tolerance may find Makers Laboratories an interesting candidate for selective exposure, particularly if the company can sustain its recent operational momentum and improve profitability metrics.
Market participants should monitor upcoming quarterly results and any shifts in the company’s financial trajectory, as well as broader sector trends, to reassess the stock’s investment potential.
Summary of Key Metrics
As of 23 June 2026, Makers Laboratories Ltd trades at ₹147.80, down 2.09% on the day. Its valuation metrics include a PE ratio of 37.11, price-to-book of 1.20, EV/EBITDA of 5.51, and ROCE of 15.26%. The company’s recent quarterly sales and PBDIT reached ₹35.75 crores and ₹5.27 crores respectively, with a debtors turnover ratio of 7.08 times. Despite a 71.7% decline in profits over the past year, the stock has delivered a modest 0.44% return in the same period, outperforming the Sensex’s negative returns year-to-date.
Conclusion
The upgrade of Makers Laboratories Ltd’s investment rating to Hold reflects a nuanced view of its current standing. Attractive valuation metrics and recent positive financial trends have improved the outlook, but persistent challenges in profitability and long-term growth temper enthusiasm. Investors should approach the stock with measured expectations, considering it as a potential value play within the Pharmaceuticals & Biotechnology micro-cap space.
Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today
